RNL Bio Filed Phase II/III Clinical Trial with KFDA to Treat Cerebral Palsy Using Autologous Fat Derived Stem Cells /PRNewswire/ -- RNL BIO CO LTD announced today the filing of an Investigational New Drug application with the Korean Food and Drug Administration to initiate clinical trials phase II and III assessing the company's RNL-Astrostem stem ... (more)
http://www.biospace.com/news_story.aspx?StoryID=287275&full=1
http://www.biospace.com/news_story.aspx?StoryID=287275&full=1
No comments:
Post a Comment